MedTrace Logo

Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT01078311 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2010-03-02

No results posted yet for this study

Summary

Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Conditions

  • Hepatocellular Cancer

Sponsors & Collaborators

  • South West Sydney Local Health District

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-02-29
Completion
2014-02-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078311 on ClinicalTrials.gov